"Pyrones" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Keto-pyrans.
| Descriptor ID |
D011753
|
| MeSH Number(s) |
D03.383.663.718
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Pyrones".
Below are MeSH descriptors whose meaning is more specific than "Pyrones".
This graph shows the total number of publications written about "Pyrones" by people in this website by year, and whether "Pyrones" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2008 | 1 | 0 | 1 |
| 2017 | 1 | 1 | 2 |
| 2018 | 3 | 1 | 4 |
| 2020 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Pyrones" by people in Profiles.
-
Hispidin and Lepidine E: Two Natural Compounds and Folic Acid as Potential Inhibitors of 2019-novel Coronavirus Main Protease (2019- nCoVMpro), Molecular Docking and SAR Study. Curr Comput Aided Drug Des. 2021; 17(3):469-479.
-
Raltegravir, Indinavir, Tipranavir, Dolutegravir, and Etravirine against main protease and RNA-dependent RNA polymerase of SARS-CoV-2: A molecular docking and drug repurposing approach. J Infect Public Health. 2020 Dec; 13(12):1856-1861.
-
Reckoning a fungal metabolite, Pyranonigrin A as a potential Main protease (Mpro) inhibitor of novel SARS-CoV-2 virus identified using docking and molecular dynamics simulation. Biophys Chem. 2020 09; 264:106425.
-
In silico prediction of potential inhibitors for the main protease of SARS-CoV-2 using molecular docking and dynamics simulation based drug-repurposing. J Infect Public Health. 2020 Sep; 13(9):1210-1223.
-
Gallium maltolate has in vitro antiviral activity against SARS-CoV-2 and is a potential treatment for COVID-19. Antivir Chem Chemother. 2020 Jan-Dec; 28:2040206620983780.
-
Yangonin protects against non-alcoholic fatty liver disease through farnesoid X receptor. Phytomedicine. 2019 Feb; 53:134-142.
-
2018 update to the HIV-TRePS system: the development of new computational models to predict HIV treatment outcomes, with or without a genotype, with enhanced usability for low-income settings. J Antimicrob Chemother. 2018 08 01; 73(8):2186-2196.
-
Selective inhibition of P-gp transporter by goniothalamin derivatives sensitizes resistant cancer cells to chemotherapy. J Nat Med. 2019 Jan; 73(1):226-235.
-
Yangonin protects against cholestasis and hepatotoxity via activation of farnesoid X receptor in vivo and in vitro. Toxicol Appl Pharmacol. 2018 06 01; 348:105-116.
-
AMPK activation restores ischemic post-conditioning cardioprotection in STZ-induced type 1 diabetic rats: Role of autophagy. Mol Med Rep. 2017 Sep; 16(3):3648-3656.